CAH officer Deborah Weitzman granted 39,100 performance share units

Rhea-AI Filing Summary

Deborah Weitzman, an officer listed as "CEO, PSS Segment" at Cardinal Health (CAH), was recorded as acquiring 39,100 performance share units on 08/12/2025 that are scheduled to settle on August 15, 2025.

The award is reported at a $0 price and is described as performance share units that will settle to common shares on the stated settlement date. After the reported acquisition, Ms. Weitzman’s beneficial ownership is shown as 88,229 common shares held directly. The filing shows this transaction as an acquisition (code A) and Table II reports no derivative securities.

Insights

Compensation Analyst

TL;DR: Routine equity compensation grant of 39,100 PSUs at $0 increases direct holdings to 88,229; materiality unclear without outstanding share count.

The filing documents a standard performance-based equity award recorded as an acquisition (code A) and priced at $0, indicating a grant rather than a market purchase. The units are scheduled to settle on August 15, 2025 and will convert to common shares upon settlement. No derivative securities are listed in Table II. Assessment of materiality requires the companys total outstanding share count and prior insider holdings; those figures are not provided in this form.

Corporate Governance Expert

TL;DR: Insider award aligns compensation with future performance; disclosure appears routine and compliant but impact is neutral without further context.

The Form 4 shows an officer-level recipient and documents the grant quantity, settlement date, and post-transaction direct ownership. The presence of an attorney-in-fact signature is a procedural detail confirming the reports execution. From a governance perspective, the transaction is a routine executive equity award; whether it meaningfully affects control, dilution, or incentives cannot be determined from this filing alone because outstanding share data and grant terms beyond settlement timing are not included.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEITZMAN DEBORAH

(Last) (First) (Middle)

7000 CARDINAL PLACE

(Street)

DUBLIN OH 43017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CARDINAL HEALTH INC [ CAH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PSS Segment

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/12/2025		A(1)		39,100	A	$0	88,229	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects performance share units that will settle on August 15, 2025.

Remarks:

	/s/ James E. Barnett, Attorney-in-fact	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Deborah Weitzman acquire in the Form 4 for CAH?

She acquired 39,100 performance share units, reported as an acquisition (code A).

How many Cardinal Health (CAH) shares does Deborah Weitzman beneficially own after the transaction?

The filing reports 88,229 common shares beneficially owned following the reported transaction, held directly.

What is the price and settlement schedule for the award?

The units are reported at a $0 price and are described as performance share units that will settle on August 15, 2025.

Does the Form 4 report any derivative securities for this reporting person?

No. Table II for derivative securities is empty, and the filing only documents the non-derivative performance share units.

What role does Deborah Weitzman hold at Cardinal Health according to the filing?

She is identified as an officer with the title listed as CEO, PSS Segment.